Variational AI is a startup that uses artificial intelligence (AI) and machine learning to revolutionize the field of drug discovery. The company was founded in September 2019 by a team of AI researchers, business specialists, and medicinal chemists. Their main product is the Enki™ generative AI platform, which is designed to create new drugs that can treat various diseases.

Variational AI operates in the biopharmaceutical market, working closely with partners in the industry to bring new therapeutics to market. One of their notable collaborations is with Merck Research Labs, a leading pharmaceutical company. This partnership aims to use Variational AI’s Enki™ platform to design novel and selective small molecules, which are the building blocks of many drugs.

The company's business model is based on partnerships with biopharmaceutical companies. They provide their partners with access to their AI platform, which can significantly speed up the drug discovery process. This, in turn, can reduce the cost of drug development, making it more economical.

In terms of revenue, Variational AI likely earns money through licensing their technology to their partners, charging for the use of their platform, and potentially sharing in the profits from any successful drugs that are developed using their technology.

Keywords: Artificial Intelligence, Machine Learning, Drug Discovery, Biopharmaceutical Partnerships, Enki™ Platform, Small Molecules, Drug Development, Economical Drug Discovery, Technology Licensing, Profit Sharing.